Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA lifts bar for Sun at its key Halol plant

Executive Summary

Sun Pharma can finally begin to receive US Food and Drug Administration (FDA) approvals for new products from its key Halol formulations manufacturing facility in Gujarat, India, after successfully addressing all issues in a longstanding warning.

You may also be interested in...



Manufacturing Round-Up: FDA Demands Meeting With Aurobindo Over Issues At Multiple Sites

An FDA warning letter issued to Aurobindo highlights recurring failures over several sites, while Teva is setting up a biologics development campus in the US and Nexus is investing in sterile injectables capacity.

Sun Pharma Commits To Generic Investment But Admits It Is Not Attractive In Current Environment

Sun’s MD Dilip Shanghvi made the rather frank admission during the firm’s third-quarter earnings call, maintaining that generics is nevertheless an “interesting” business for the Indian major. In light of this outlook, Sun has continued its policy of withdrawing what it feels are “unviable” ANDAs from under FDA review.

Joint Mission: FDA And VA Partner On Device Development Initiative

The US Food and Drug Administration and the Veterans Health Administration are partnering to create tools that can help novel technology reach patients more quickly and easily.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB000853

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel